市場調查報告書
商品編碼
1451061
2024-2032 年按適應症(自體免疫疾病、腫瘤、代謝紊亂等)、類別(重組蛋白、單株抗體、純化蛋白)和地區分類的生物製藥市場報告Biopharmaceutical Market Report by Indication (Autoimmune Diseases, Oncology, Metabolic Disorders, and Others), Class (Recombinant Proteins, Monoclonal Antibodies, Purified Proteins), and Region 2024-2032 |
2023年全球生物製藥市場規模達到3,005億美元。展望未來, IMARC Group預計到2032年市場規模將達到6,439億美元,2024-2032年複合年成長率(CAGR)為8.6%。對個人化藥物的需求不斷成長、慢性病和生活方式相關疾病的盛行率不斷上升,以及生物技術(包括基因工程和重組 DNA 技術)的快速進步,是推動市場成長的關鍵因素。
生物製藥,也稱為生物製劑,是一類從生物來源衍生出來的藥物。它們是利用細菌、酵母或哺乳動物細胞等活生物體透過生物技術過程生產的。與化學合成的傳統小分子藥物不同,生物製藥是大而複雜的分子,與體內的生物標靶表現出高度特異性的相互作用。與傳統藥物相比,它們具有多種優勢。它們的作用往往具有高度特異性,通常針對特定受體或分子,從而提高療效並減少副作用。此外,生物製藥有可能治療先前使用傳統藥物難以解決的疾病。
由於對個人化醫療的需求不斷成長,該市場正在經歷顯著成長。此外,擴大利用生物製藥來治療癌症、糖尿病、牛皮癬和類風濕性關節炎,這是另一個主要的生長誘導因素。此外,大眾對生物製藥的有效性和可用性的認知不斷增強,這是另一個主要的成長誘導因素。此外,對罕見疾病和孤兒藥的日益關注正在推動市場的成長。這些罕見疾病的特徵通常是患者群體較少,但醫療需求卻未被滿足。除此之外,世界各地的政府和監管機構還推出了激勵措施並簡化了監管流程,以鼓勵開發這些疾病的療法。此外,生物製藥公司正在投資研發,開發針對罕見疾病的孤兒藥,從而滿足關鍵的醫療需求並創造市場擴張機會。
對個人化醫療的需求不斷成長
個人化醫療導致生物製藥市場轉向標靶治療和精準醫療方法。生物製藥公司越來越注重開發針對特定基因突變、生物標記或與疾病相關的分子途徑的療法。此外,個人化醫療帶來了藥物基因組學的進步,藥物基因組學是研究個體的基因組成如何影響其對藥物的反應。了解影響藥物代謝、功效和安全性的遺傳變異可以識別可能面臨不良反應風險的患者或更有可能對特定治療產生良好反應的患者。這些知識使生物製藥公司能夠開發針對個別患者的針對性療法和劑量方案,從而提高治療效果並降低不良事件的風險。
慢性病和生活方式相關疾病的盛行率不斷上升
慢性疾病,包括心血管疾病、糖尿病、癌症、呼吸系統疾病和自體免疫疾病,已成為全球主要的健康挑戰。這些疾病往往具有複雜的潛在機制,需要有針對性和個人化的治療方法。生物製藥,如單株抗體、重組蛋白和基因療法,提供精確的標靶和客製化的治療選擇。這些療法可以針對與慢性疾病相關的特定分子途徑、受體或細胞,從而提高療效並減少副作用。此外,慢性病和生活方式相關疾病的負擔日益增加,已將重點從症狀緩解轉向疾病改變和預防,這也推動了市場的成長。
生物技術的各種進步
生物技術大大加速了藥物發現和開發進程。高通量篩選、組合化學和計算建模等先進技術可以在更短的時間內鑑定和測試大量候選藥物。這提高了藥物發現的效率和速度,使生物製藥公司能夠更快地將新療法推向市場。此外,分析個別基因組成、識別疾病標記和了解分子途徑的能力使得能夠開發針對特定患者群體的標靶療法。基因組學、下一代定序和基因編輯技術等生物技術工具徹底改變了對疾病機制的理解,並促進了針對特定遺傳變異和分子標靶的療法的開發,從而推動了市場的發展。
The global biopharmaceutical market size reached US$ 300.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 643.9 Billion by 2032, exhibiting a growth rate (CAGR) of 8.6% during 2024-2032. The escalating demand for personalized medicines, the growing prevalence of chronic and lifestyle-related diseases, and rapid advancements in biotechnology, including genetic engineering and recombinant DNA technology, are among the key factors driving the market growth.
Biopharmaceuticals, also known as biologics, are a class of pharmaceutical drugs derived from biological sources. They are produced using living organisms, such as bacteria, yeast, or mammalian cells, through biotechnological processes. Unlike traditional small-molecule drugs, which are chemically synthesized, biopharmaceuticals are large, complex molecules that exhibit highly specific interactions with biological targets in the body. They offer several advantages over traditional pharmaceuticals. They tend to be highly specific in their action, often targeting specific receptors or molecules, resulting in increased efficacy and reduced side effects. Additionally, biopharmaceuticals have the potential to treat diseases that were previously challenging to address using conventional drugs.
The market is experiencing significant growth due to the escalating demand for personalized medicine. In addition, the increasing utilization of biopharmaceuticals to treat cancer, diabetes, psoriasis, and rheumatoid arthritis represents another major growth-inducing factor. Besides, the growing awareness among the masses regarding the effectiveness and availability of biopharmaceuticals represents another major growth-inducing factor. Moreover, the rising focus on rare diseases and orphan drugs is driving the growth of the market. These rare diseases, often characterized by small patient populations, present significant unmet medical needs. Other than this, governments and regulatory agencies worldwide have introduced incentives and streamlined regulatory processes to encourage the development of therapies for these conditions. Moreover, biopharmaceutical companies are investing in R&D to develop orphan drugs, which target rare diseases, thereby addressing critical medical needs and creating opportunities for market expansion.
The escalating demand for personalized medicine
Personalized medicine has led to a shift toward targeted therapies and precision medicine approaches in the biopharmaceutical market. Biopharmaceutical companies are increasingly focusing on the development of therapies that target specific genetic mutations, biomarkers, or molecular pathways associated with diseases. Moreover, personalized medicine has led to advancements in pharmacogenomics, which is the study of how an individual's genetic makeup influences their response to drugs. Understanding the genetic variations that impact drug metabolism, efficacy, and safety allows for the identification of patients who may be at risk of adverse reactions or those who are more likely to respond favorably to a specific treatment. This knowledge enables biopharmaceutical companies to develop targeted therapies and dosage regimens tailored to individual patients, enhancing treatment effectiveness and reducing the risk of adverse events.
The growing prevalence of chronic and lifestyle-related diseases
Chronic diseases, including cardiovascular disorders, diabetes, cancer, respiratory diseases, and autoimmune conditions, have become major global health challenges. These diseases often have complex underlying mechanisms, requiring targeted and personalized treatment approaches. Biopharmaceuticals, such as monoclonal antibodies, recombinant proteins, and gene therapies, offer precise targeting and tailored treatment options. These therapies can target specific molecular pathways, receptors, or cells associated with chronic diseases, resulting in enhanced efficacy and reduced side effects. Moreover, the increasing burden of chronic and lifestyle-related diseases has shifted the focus from symptomatic relief to disease modification and prevention, which is also propelling the market growth.
Various advancements in biotechnology
Biotechnology has greatly accelerated the drug discovery and development process. Advanced techniques, such as high-throughput screening, combinatorial chemistry, and computational modeling, enable the identification and testing of a large number of drug candidates in a shorter time frame. This has led to an increase in the efficiency and speed of drug discovery, allowing biopharmaceutical companies to bring new therapies to market more rapidly. Besides, the ability to analyze an individual's genetic makeup, identify disease markers, and understand molecular pathways has enabled the development of targeted therapies tailored to specific patient populations. Biotechnology tools, such as genomics, next-generation sequencing, and gene editing techniques, have revolutionized the understanding of disease mechanisms and enabled the development of therapies that address specific genetic variations and molecular targets, thus propelling the market.
IMARC Group provides an analysis of the key trends in each segment of the global biopharmaceutical market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on indication and class.
Autoimmune Diseases
Oncology
Metabolic Disorders
Others
Autoimmune diseases represent the leading segment
The report has provided a detailed breakup and analysis of the market based on the indication. This includes autoimmune diseases, oncology, metabolic disorders, and others. According to the report, autoimmune diseases represented the largest segment.
Autoimmune diseases are often chronic and complex conditions that require long-term management and treatment. These diseases can affect multiple organs and systems in the body, leading to a wide range of symptoms and complications. Biopharmaceutical therapies have shown promising results in managing and controlling autoimmune diseases, providing relief from symptoms, slowing disease progression, and improving quality of life for patients. Therapies, including monoclonal antibodies and other biologics, have emerged as a vital treatment option for autoimmune diseases. They target specific molecules, cells, or pathways involved in the autoimmune response, providing more precise and effective therapeutic interventions.
Recombinant Proteins
Monoclonal Antibodies
Purified Proteins
Monoclonal antibodies exhibit a clear dominance in the market
A detailed breakup and analysis of the market based on the class has also been provided in the report. This includes recombinant proteins, monoclonal antibodies, and purified proteins. According to the report, monoclonal antibodies accounted for the largest market share.
Monoclonal antibodies are highly specific in targeting disease-specific antigens or cells. They are designed to bind to a specific target with precision, minimizing off-target effects and reducing the risk of adverse reactions. This specificity contributes to their efficacy in treating various diseases, including autoimmune disorders, cancer, inflammatory conditions, and infectious diseases. They also have a wide range of therapeutic applications across different disease areas. They can be used as therapeutic agents on their own or in combination with other treatments. Monoclonal antibodies have been successful in neutralizing pathogens, blocking cell receptors, modulating immune responses, and delivering therapeutic payloads, making them versatile tools for disease management.
North America
United States
Canada
Latin America
Mexico
Brazil
Argentina
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Turkey
Asia Pacific
Japan
China
Australia
South Korea
India
Indonesia
North America accounts for the majority of market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Latin America (Mexico, Brazil, and Argentina); Europe (Germany, France, Italy, Spain, the United Kingdom, Russia, and Turkey); and Asia Pacific (Japan, China, Australia, South Korea, India, and Indonesia). According to the report, North America was the largest market for biopharmaceuticals.
North America, particularly the United States, boasts a highly developed healthcare infrastructure, including robust research and development capabilities, advanced clinical facilities, and a strong regulatory framework. The region is home to renowned academic institutions, pharmaceutical companies, and research organizations that drive innovation in the biopharmaceutical industry. The presence of these institutions and infrastructure facilitates the development, manufacturing, and commercialization of biopharmaceutical products. The region has a well-established ecosystem that supports biopharmaceutical innovation, including government funding initiatives, research grants, venture capital investments, and collaborations between academia, industry, and research institutes.
The competitive landscape of the biopharmaceutical market is highly dynamic and competitive, with numerous global and regional players vying for market share. Nowadays, leading biopharmaceutical companies are heavily investing in R&D to discover and develop innovative therapies. They are conducting preclinical and clinical trials, and advance promising candidates through the regulatory approval process. These investments aim to expand their product pipelines, address unmet medical needs, and stay ahead of competitors in terms of therapeutic advancements. They are also forming strategic partnerships and collaborations with academic institutions, research organizations, and other industry players. These alliances enable them to access new technologies, scientific expertise, and complementary resources.
AbbVie Inc.
Amgen Inc
Biogen Inc.
Eli Lilly and Company
F. Hoffmann-La Roche AG
Johnson & Johnson
Merck & Co. Inc.
Novo Nordisk A/S
Pfizer Inc.
Sanofi S.A
Pfizer and BioNTech developed and distributed their mRNA-based COVID-19 vaccine, Comirnaty (BNT162b2). The vaccine received emergency use authorizations and has been widely deployed globally, playing a crucial role in combating the COVID-19 pandemic.
Amgen Inc. recently received FDA approval for Lumakras (sotorasib), a targeted therapy for non-small cell lung cancer (NSCLC) with specific genetic mutations.
AbbVie Inc. has made significant advancements in immunology, particularly with its flagship product, Humira (adalimumab). Humira is one of the world's best-selling biologic drugs used to treat autoimmune conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease.